Ulcerative colitis

Lancet

Volumn 359, Issue 9303, 2002, Pages 331-340

  Farrell, Richard J ^a   Peppercorn, Mark A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZATHIOPRINE; CIPROFLOXACIN; FISH OIL; FOROPAFANT; HEPARIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 10; RIFAXIMIN; THIOPURINE METHYLTRANSFERASE; TIOGUANINE;

CANCER RISK; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; INTESTINE FLORA; PATHOGENESIS; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 0037176571     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07499-8     Document Type: Conference Paper

References (160)

1. Evolving treatment strategies for inflammatory bowel disease
2. Inflammatory bowel disease: Etiology and pathogenesis
3. Microbial factors in the pathogenesis of Crohn's disease, ulcerative colitis, and experimental intestinal inflammation
4. Concordance of inflammatory bowel disease among Danish twins: Results of a nationwide study
5. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking
6. Role of smoking in inflammatory bowel disease: Implications for therapy
7. Smoking and inflammatory bowel disease: A case control study
8. Reversible alterations in immunoregulatory T cells in smoking: Analysis by monoclonal antibodies and flow cytometry
9. Smoking, humoral immunity, and ulcerative colitis
10. Smoking and colonic mucus in ulcerative colitis
11. Colonic motility in chronic ulcerative proctosigmoiditis and the effects of nicotine on colonic motility in patients and healthy subjects
12. The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease
13. In-vivo effect of nicotine on cytokine production by human non-adherent mononuclear cells
14. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease
15. Selective COX-2 inhibitors and human inflammatory bowel disease
16. Increased risk of inflammatory bowel disease associated with oral contraceptive use
17. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: A nationwide case-control study - Cooperative investigators of the Italian Group for the study of the colon and the rectum (GISC)
18. Patient perceptions of causes of inflammatory bowel disease
19. Stress and immunity in humans: A meta-analytic review
20. The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis
21. Stress and exacerbation in ulcerative colitis: A prospective study of patients enrolled in remission
22. Characterization of spontaneous colitis in cotton-top tamarins (Saguinus oedipus) and its response to sulfasalazine
23. Insecure attachment in a subgroup with ulcerative colitis defined by ANCA status
24. Childhood infections and the risk of inflammatory bowel disease
25. Appendectomy protects against ulcerative colitis
26. Appendectomy and the development of ulcerative colitis: Results of a metaanalysis of published case-control studies
27. Appendectomy and protection against ulcerative colitis
28. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice
29. A patient with improvement of ulcerative colitis after appendectomy
30. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea
31. Absence of Escherichia coli, Listeria monocytogenes, and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues
32. Glycoprotein composition of colonic mucosa: Specific alterations in ulcerative colitis
33. Colonic mucus and mucosal glycoproteins: The key to colitis and cancer?
34. Impaired defence of intestinal mucosa in mice lacking intestinal trefoil factor
35. Autoantibodies in human ulcerative colitis
36. The search for pathogenic antigens in ulcerative colitis
37. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease
38. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease
39. Neutrophil cytoplasmic antibodies: A link between primary sclerosing cholangitis and ulcerative colitis
40. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: Results of a pilot study
41. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis
42. Antineutrophil cytoplasmic antibodies in relatives of patients with inflammatory bowel disease
43. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis
44. A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody
45. Autoimmunity in ulcerative colitis: Tropomyosin is not the major antigenic determinant of the Das monoclonal antibody, 7E12H12
46. Surface-exposed conserved region of the streptococcal M protein induces antibodies cross-reactive with denatured forms of myosin
47. Mast cell and neuroendocrine cytoplasmic autoantigen(s) detected by monoclonal pANCA antibodies
48. Definition of ocular antigens in ciliary body and retinal ganglion cells by the marker antibody pANCA
49. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope
50. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup
51. Familial occurrence of inflammatory bowel disease
52. Familial empirical risks for inflammatory bowel disease: Differences between Jews and non-Jews
53. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease
54. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease
55. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12
56. HLA-DRB1*1502 allele, subtype of DR15, is associated with susceptibility to ulcerative colitis and its progression
57. Genetic markers may predict disease behavior in patients with ulcerative colitis
58. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy
59. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease
60. Genetic heterogeneity within ulcerative colitis determined by an interleukin-1 receptor antagonist gene polymorphism and antineutrophil cytoplasmic antibodies
61. Association of ulcerative colitis with rare VNTR alleles of the human intestinal mucin gene, MUC3
62. Epithelial deposits of immunoglobulin G1 and activated complement co-localize with the "M(r) 40kD" putative auto-antigen in ulcerative colitis
63. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases
64. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice
65. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans
66. Stimulated human lamina propria T cells manifest enhanced Fas-mediated apoptosis
67. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis
68. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5
69. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: Correlation with disease activity
70. The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice
71. Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40-CD154 interactions
72. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
73. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance
74. Therapy of inflammatory bowel disease
75. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate
76. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis (Cochrane Review)
77. Oral 5-aminosalicylic acid for maintaining remission in ulcerative colitis (Cochrane Review)
78. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis
79. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: A randomized double-blind study
80. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study - US Budesonide enema study group
81. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis
82. A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis
83. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis
84. Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis
85. The natural history of corticosteroid therapy for inflammatory bowel disease
86. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis
87. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis
88. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
89. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
90. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial
91. Mycophenolate mofetil
92. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: A 12-month pilot study
93. Cyclosporine in severe ulcerative colitis refractory to steroid therapy
94. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis: Belgian IBD group
95. Intravenous cyclosporine in attacks of ulcerative colitis: Short-term and long-term responses
96. Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease
97. Complications during cyclosporine therapy for inflammatory bowel disease
98. Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia
99. Two and four mg/kg of intravenous cyclosporin are equally effective in severe attacks of ulcerative colitis
100. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis
101. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis
102. Intravenous cyclosporin in ulcerative colitis: A five-year experience
103. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin
104. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: An open-label retrospective trial
105. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis
106. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis
107. Pharmacotherapy for inducing and maintaining remission in pouchitis (Cochrane Review)
108. Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-blind, placebo-controlled study
109. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial
110. Probiotics and inflammatory bowel disease: Is there a scientific rationale?
111. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
112. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
113. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis
114. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebocontrolled trial
115. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
116. Fish oil fatty acid supplementation in active ulcerative colitis: A double-blind, placebo-controlled, crossover study
117. Dietary supplementation with fish oil in ulcerative colitis
118. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis
119. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis
120. Transdermal nicotine for active ulcerative colitis
121. Transdermal nicotine for mildly to moderately active ulcerative colitis: A randomized, double-blind, placebo-controlled trial
122. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis
123. Transdermal nicotine as maintenance therapy for ulcerative colitis
124. Nicotine enemas for active ulcerative colitis - A pilot study
125. Treatment of left-sided ulcerative colitis with butyrate enemas: A controlled trial
126. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: A randomised, placebo controlled trial
127. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis
128. Heparin, cell adhesion, and pathogenesis of inflammatory bowel disease
129. Review article: Potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease
130. Treatment of corticosteroid-resistant ulcerative colitis with heparin: A report of 16 cases
131. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis
132. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease
133. Tacrolimus (FK506): A new immunosuppressant for steroid refractory inflammatory bowel disease
134. Infliximab is an effective therapeutic agent for ulcerative colitis
135. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
136. Treatment of ulcerative colitis with an engineered human anti-TNF alpha antibody CDP571
137. The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: Characterisation, genetics and clinical application: Focus on TNF alpha
138. Ulcerative colitis and colorectal cancer: A population-based study
139. Family history as a risk factor for colorectal cancer in inflammatory bowel disease
140. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: Fact or fiction?
141. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis
142. Colorectal cancer prevention in ulcerative colitis: A case-control study
143. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study
144. Mesalazine-induced apoptosis of colorectal cancer: On the verge of a new chemopreventive era?
145. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis
146. Risk factors and distinguishing features of cancer in IBD
147. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?
148. Surveillance issues in inflammatory bowel disease: Ulcerative colitis
149. The Vienna classification of gastrointestinal epithelial neoplasia
150. Evaluation of surveillance programmes for colorectal cancer in ulcerative colitis patients by case-control studies: Methodological considerations
151. Ulcerative colitis practice guidelines in adults - American college of gastroenterology, practice parameters committee
152. How gastroenterologists screen for colonic cancer in ulcerative colitis: An analysis of performance
153. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis
154. Colonoscopic polypectomy in chronic colitis: Conservative management after endoscopic resection of dysplastic polyps
155. Monozygotic twins with Crohn's disease and ulcerative colitis: A unique case report
156. Seasonal variations in the onset of ulcerative colitis
157. Leukotrienes in ulcerative colitis: Results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591
158. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis - The European zileuton study group for ulcerative colitis
159. Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: A randomized controlled trial
160. Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis